HTA60 Icosapent Ethyl in Addition to Statins Is a Cost-Effective Treatment in Patients at High Cardiovascular Risk With Elevated Triglycerides and Established Cardiovascular Disease or Diabetes With Risk Factor in the Netherlands
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1520
https://www.valueinhealthjournal.com/article/S1098-3015(22)03725-1/fulltext
Title :
HTA60 Icosapent Ethyl in Addition to Statins Is a Cost-Effective Treatment in Patients at High Cardiovascular Risk With Elevated Triglycerides and Established Cardiovascular Disease or Diabetes With Risk Factor in the Netherlands
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03725-1&doi=10.1016/j.jval.2022.09.1520
First page :
Section Title :
Open access? :
No
Section Order :
11072